Company Encyclopedia
View More
name
HUAKANG BIOMED
08622.HK
Huakang Biomedical Holdings Company Limited, an investment holding company, engages in the research, production, and sale of male fertility in-vitro diagnostic (IVD) reagents in the People's Republic of China. The company provides biological reagents, including male fertility IVD reagents, parasite antibody detection reagents, and Epstein-Barr virus antibody detection reagent; and auxiliary reproductive supplies and equipment. The company sells its products directly to hospitals and medical institutions, as well as to distributors. Huakang Biomedical Holdings Company Limited was founded in 1992 and is based in Tsim Sha Tsui, Hong Kong.
80.41 B
08622.HKMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
Health Care SuppliesIndustry
Industry Ranking10/13
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-8.75%D
    • Profit Margin-18.42%D
    • Gross Margin68.26%A
  • Growth ScoreC
    • Revenue YoY2.90%C
    • Net Profit YoY22.12%B
    • Total Assets YoY1.81%C
    • Net Assets YoY-6.14%D
  • Cash ScoreD
    • Cash Flow Margin-542.75%E
    • OCF YoY2.90%C
  • Operating ScoreC
    • Turnover0.39C
  • Debt ScoreA
    • Gearing Ratio22.01%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Hong Kong Stock Movement: HUAKANG BIOMED plummets 21.57%, active trading attracts market attention

    HUAKANG BIOMED fell 21.57%; Weigao Group's trading volume reached HKD 10.34 million; Kangnai Optical rose 2.74%, with a trading volume of HKD 5.46 million; YingTai Medical rose 1.41%, with a trading volume of HKD 603,200; China National Nuclear Power rose 0.19%, with a market value of HKD 6.781 billion

    HK Stock Movers Tracker·
    HK
    08622
    -21.00%
    HK Stock Movers Tracker·
    HK
    08622
    -21.00%

    Huakang Biomedical Sends Out Composite Document for Anselme Buyout Offer

    Anselme Limited has issued a composite document for its offer to acquire all shares of Huakang Biomedical Holdings Co. Ltd. and cancel outstanding share options. This follows previous announcements about the acquisition agreement and document dispatch delay. The document details mandatory unconditional cash offers.

    Reuters·
    HK
    08622
    -21.00%
    Reuters·
    HK
    08622
    -21.00%

    Huakang Biomedical Files Director List with HKEX

    Huakang Biomedical Holdings Co. Ltd. has filed its updated list of directors with the Hong Kong Stock Exchange. The board includes four executive directors, two non-executive directors, and three independent non-executive directors. The company has also established three committees: Audit, Remuneration, and Nomination, each chaired by different directors. This filing is part of the company's corporate governance updates.

    Reuters·
    HK
    08622
    -21.00%
    Reuters·
    HK
    08622
    -21.00%

    Huakang Biomedical Delays Dispatch of Composite Document for Anselme Buyout

    Anselme Limited has postponed the dispatch of the composite document regarding its plan to acquire all shares of Huakang Biomedical Holdings. This includes the cancellation of all outstanding share options not already owned or agreed to be acquired by Anselme and its concert parties. Further details will be provided later, as stated in a joint announcement from both companies.

    Reuters·
    HK
    08622
    -21.00%
    Reuters·
    HK
    08622
    -21.00%

    The Hong Kong stock market's pharmaceutical and biotechnology sector leads in gains

    On October 27th, the Hong Kong stock market saw significant gains in the pharmaceuticals and biotechnology sector. XUANZHUBIO-B rose nearly 19%, CANBRIDGE-B increased over 14%, SINOMAB BIO-B climbed over 11%, BAIOO SAI TU-B and HUAKANG BIOMED both surged over 9%, and JW THERAP-B rose over 8%

    Zhitong·
    HK
    02575
    +2.78%
    HK
    01228
    +2.60%
    HK
    03681
    -0.66%
    Zhitong·
    HK
    02575
    +2.78%
    HK
    01228
    +2.60%
    HK
    03681
    -0.66%
    © 2025 Longbridge｜Disclaimer